NEWS: 公告在東京證券交易所JASDAQ標準市場新上市


生命科學分析的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Life Sciences Analytics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 708576
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
生命科學分析的全球市場 - 成長,趨勢,預測(2019年∼2024年) Life Sciences Analytics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 115 Pages




第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 醫藥品及臨床試驗的分析解決方案的採用增加
    • 為了削減醫療費的壓力高漲和患者轉換期的改善必要性
    • 生命科學企業的先進分析技術的登場
  • 市場阻礙因素
    • 熟練人力資源的不足
    • 實行成本高
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各產品類型
    • 說明的分析
    • 預測的分析
    • 指示性分析
  • 各用途
    • 研究開發
    • 供應鏈分析
    • 銷售、行銷
    • 其他
  • 各零件
    • 服務
    • 軟體
  • 各終端用戶
    • 臨床研究機關
    • 製藥、生物科技企業
    • 醫療設備廠商
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Accenture
    • Cognizant
    • IBM Corporation
    • MaxisIT Inc.
    • Oracle Corporation
    • IQVIA
    • SAS Institute Inc.
    • SCIOInspire, Corp.
    • TAKE Solutions Limited
    • Wipro Limited

第7章 市場機會及未來趨勢


Product Code: 62770

The major factors for the growth of the life sciences analytics market include the rising adoption of analytics solutions in pharmaceuticals and clinical trials, growing pressure to reduce healthcare spending, need for improved patient outcomes, and the emergence of advanced analytics methods in life science companies.

There is a rise in the use of analytics in clinical trials, as conducting clinical trials has become complex, because it involves many activities and generates high volumes of data from different systems. With the changing regulatory protocol requirements for clinical trial conduction and challenge in data collection, analyzing, and preparing a report quickly for submission to the health authority, the adoption of analytics of clinical trials is on the rise.

Analytics may help in optimizing drug discovery, improving the efficiency of clinical trials. With the huge data generated from the R&D process and clinical research, pharma companies can identify potential drug candidates with a high probability of successfully developing into drugs. Most contract research organizations (CROs) with established systems for data capture and advanced analytics are now incorporated across all systems, such as drug discovery and clinical development, which are providing real-time analysis and creating alerts to each divisions concerning safety or efficacy. The application of analytics in evaluating a potential drug candidate for clinical development may reduce the time and R&D expenditure. Therefore all the above-mentioned factors may increase the application of analytics in life sciences and the related companies, and thereby, lead to the growth of the market studied.

Key Market Trends

Clinical Research Institutions is Expected to Witness the Fastest Growth over the Forecast Period

Analytics in clinical research helps the pharmaceutical companies to analyze data, for the comparison of ongoing trials at different sites and populations, preparation of reports for submission to the regulatory authority, and for getting approvals. Analytics in clinical trials is useful in understanding the outcome of the trial at each phase (Phase I, II, III, IV). This becomes a decisive factor in situations, such as whether to go forward with the trial or to stop the trial, submission of the clinical data report as required by regulatory authorities, at the earliest, and prevention of the delay of regulatory approval.

There is also increasing funding for research and development by healthcare companies. The global pharmaceutical industry investment in research and development has increased over the years, from USD 108.1 billion in 2006 to USD 156.7 billion in 2016, as per a 2017 report by the Association of the British Pharmaceutical Industry. Hence, with the increasing expenditure in R&D, this market in the pharmaceutical industry is expected to attain good growth over the forecast period.

North America is Expected to Dominate the Life Sciences Analytics Market

The life sciences and pharmaceutical industries are facing challenges related to R&D and regulatory changes. The introduction of the Affordable Care Act (ACA) in the United States is changing the regulatory framework, increasing scrutiny, and reimbursing, based on the health outcomes. To tackle these challenges, most companies in the United States are implementing analytics on their own or are using third-party analytics services for support.

Analytics solutions are creating an impact that is providing simple reporting solutions to descriptive and predictive analytic solutions. The companies based in the United States are adopting new analytics solutions in their business, which include the analysis of clinical research data from the SAS database, helpful in early-stage drug development, analyzing adverse event incidence and reporting in clinical trials, and revenue forecasting and prediction of health outcomes.

With the life sciences and pharmaceutical companies leveraging support from third-party solution providers in clinical development, trial planning, cohort building, market analytics, and patient analytics, the US life science analytics market is expected to witness high growth over the forecast period.

Competitive Landscape

The market studied is a fragmented one owing to the presence of various players. Some of the market players are Accenture, Cognizant, IBM Corporation, MaxisIT Inc., Oracle Corporation, IQVIA, SAS Institute Inc., SCIOInspire Corp., TAKE Solutions Limited, and Wipro Limited.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption of Analytics Solutions in Pharmaceuticals and Clinical Trials
    • 4.2.2 Growing Pressure to Reduce Healthcare Spending and the Need for Improved Patient Outcomes
    • 4.2.3 Emergence of Advanced Analytics Method in Life Science Companies
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Personnel
    • 4.3.2 High Implementation Costs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product Type
    • 5.1.1 Descriptive Analytics
    • 5.1.2 Predictive Analytics
    • 5.1.3 Prescriptive Analytics
  • 5.2 By Application
    • 5.2.1 Research and Development
    • 5.2.2 Supply Chain Analytics
    • 5.2.3 Sales and Marketing
    • 5.2.4 Other Applications
  • 5.3 By Component
    • 5.3.1 Services
    • 5.3.2 Software
  • 5.4 By End User
    • 5.4.1 Clinical Research Institutions
    • 5.4.2 Pharmaceutical and Biotechnology Companies
    • 5.4.3 Medical Device Companies
    • 5.4.4 Other End User
  • 5.5 Geography
    • 5.5.1 North America
      • United States
      • Canada
      • Mexico
    • 5.5.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.5.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.5.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Accenture
    • 6.1.2 Cognizant
    • 6.1.3 IBM Corporation
    • 6.1.4 MaxisIT Inc.
    • 6.1.5 Oracle Corporation
    • 6.1.6 IQVIA
    • 6.1.7 SAS Institute Inc.
    • 6.1.8 SCIOInspire Corp.
    • 6.1.9 TAKE Solutions Limited
    • 6.1.10 Wipro Limited